copegus 200 mg filmovertrukne tabletter
roche a/s - ribavirin - filmovertrukne tabletter - 200 mg
copegus 400 mg filmovertrukne tabletter
roche a/s - ribavirin - filmovertrukne tabletter - 400 mg
copegus 200 mg filmovertrukne tabletter
orifarm a/s - ribavirin - filmovertrukne tabletter - 200 mg
copegus 400 mg filmovertrukne tabletter
orifarm a/s - ribavirin - filmovertrukne tabletter - 400 mg
lescol 40 mg kapsler, hårde
novartis healthcare a/s - fluvastatinnatrium - kapsler, hårde - 40 mg
avipro ae oral suspension til brug i drikkevand
lohmann animal health gmbh - aviær encephalomyelitis virus, stamme 1143 calnek (levende, svækket) - oral suspension til brug i drikkevand - fjerkræ
avipro gumboro vac pulver til opløsning i drikkevand
lohmann animal health gmbh - infektiøs bursitis virus, stamme cu 1, frysetørret (levende) - pulver til opløsning i drikkevand - fjerkræ
hipragumboro cw lyofilisat til anvendelse i drikkevand
laboratorios hipra s.a. - infektiøs bursitis virus, stamme ch/80, frysetørret (levende) - lyofilisat til anvendelse i drikkevand - fjerkræ
carvykti
janssen-cilag international nv - ciltacabtagene autoleucel - multipelt myelom - carvykti is indicated for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti-cd38 antibody and have demonstrated disease progression on the last therapy.
adempas
bayer ag - riociguat - hypertension, lunge - antihypertensive midler til pulmonal arteriel hypertension - chronic thromboembolic pulmonary hypertension (cteph)adempas is indicated for the treatment of adult patients with who functional class (fc) ii to iii withinoperable cteph,persistent or recurrent cteph after surgical treatment,to improve exercise capacity. pulmonary arterial hypertension (pah)adultsadempas, as monotherapy or in combination with endothelin receptor antagonists, is indicated for the treatment of adult patients with pulmonary arterial hypertension (pah) with who functional class (fc) ii to iii to improve exercise capacity. effekten har været vist i en pah befolkningen, herunder aetiologies af idiopatisk eller arvelige pah eller pah, der er forbundet med bindevævssygdom. paediatricsadempas is indicated for the treatment of pah in paediatric patients aged less than 18 years of age and body weight ≥ 50 kg with who functional class (fc) ii to iii in combination with endothelin receptor antagonists.